Mondaca et al. (2021) tested 736 plasma samples with the Resolution ctDNA NGS and identified ALK fusion in 21 patient samples. They also discovered new ALK fusion partners (EML4, CLTC, and PON1S) and compared their findings with results from tissue biopsies, showing a concordance rate of 93%. This suggests that the Resolution NGS tool can be used to detect ALK fusions in lung cancer patients (Mondaca et al., 2021). Here, ALK is linked to lung carcinoma.